Society collaboration release management guideline for Turner syndrome
Posted: 14 July 2017 | Niamh Marriott (Junior Editor: European Pharmaceutical Review) | 1 comment
A comprehensive, international guideline that incorporates the most up-to-date knowledge on diagnosis, treatment and patient impact of Turner syndrome (TS) has been published.
The guideline project was initiated by the European Society for Endocrinology (ESE) and the Paediatric Endocrine Society (PES), in collaboration with six other learned societies, to incorporate the latest evidence-based advice for diagnosis and treatment of girls and women with TS.
TS is a rare genetic disorder that affects only girls and occurs when all or part of one X chromosome is missing, affecting approximately 1/2000 female births. TS has many health implications for patients at different stages of their life – it alters growth during childhood and teenage years, delays puberty, and adversely affects cardiovascular health and fertility in adulthood. TS is also associated with neurocognitive issues, which can result in patients having difficulties in everyday tasks such as navigating through a city, or experiencing social interaction issues.
If not diagnosed and treated appropriately, TS can be associated with higher mortality rates and preventable complications. Although previous guidelines have highlighted the importance of a multidisciplinary approach to manage TS patients, there have been many recent advances since their publication.
The revised guideline addresses all health issues related to the condition, including psychological and social implications, providing clinicians with recommendations on how to treat patients at all stages – from foetal life into old age. Using evidence-based advice the updated guidance includes improved recommendations on optimal growth-promoting therapy, dealing with cardiovascular problems and tackling infertility in TS patients.
Professors Claus Gravholt and Philippe Backeljauw, Co-Chairs of the guideline consensus working group, agree that in particular, “the new cardiovascular-related advice should lead to lower morbidity and mortality, while the recommendations on oestrogen replacement therapy and guidance for pregnancy consideration should lead to improved quality of life.”
The new guidelines were developed from the findings of over 576 TS studies by ESE and PES, in collaboration with the Endocrine Society, the European Society for Pediatric Endocrinology, European Society of Human Reproduction and Embryology, the American Heart Association, the Society for Endocrinology, and the European Society of Cardiology.
“We envision that these guidelines will be widely adopted around the world by the professional communities and become the framework to treat TS, however, more future well-designed and large studies are needed in order to keep establishing evidence-based recommendations.” states Professor Gravholt.